Thursday, September 27, 2018 9:12:01 AM
10:39 26 Sep 2018
Progression Free Survival is the primary endpoint of the study and not the Overall Response Rate
The chief executive of TG Therapeutics Inc (NASDAQ:TGTX) said Wednesday the negative reaction to the results of the Unity-CLL Phase 3 trial for treating leukemia was misunderstood by the market when it punished the company's stock harshly in the previous session.
"We believe the market reaction was overblown and misplaced," TG Therapeutics CEO Michael Weiss told Proactive Investors in an email interview. "We can understand that the timelines needed to be adjusted which could cause a modest price decline but the thesis floating around that this news lowers the probability of success of UNITY-CLL is incorrect in our opinion."
The Data Safety Monitoring Board (DSMB) said the results were not sufficient to conduct an Overall Response Rate (ORR) analysis for the drug treating leukemia.
Shares fell to a fresh 52-week low at $5 before recovering to trade just 0.5% down at $5.12 in morning trade. The stock tumbled Tuesday after the news and finished at $5.15.
READ: TG Therapeutics stock sinks after Phase 3 test of leukemia treatment falters, but still has 5 key tests in the pipeline
Weiss said the study for the drug "was designed under the assumption that the driver of improvement in Progression Free Survival (PFS) (is) the primary endpoint for the study."
That is so "because our U2 combination would have a significantly better durability of response not by materially increasing the number of people responding (or ORR). So in essence, even if we had the same number of responders, if each responder in the U2 arm on average survived without progression twice as long as the control arm responders, U2 would be successful in the PFS outcome."
The DSMB seems to bear him out. It said after reviewing the data, there were no safety concerns and recommended the trial continue without any modification.
TG-1101 (ublituximab) is a glycoengineered monoclonal antibody that targets a specific and unique epitope on the CD20 antigen found on mature B-lymphocytes. TG Therapeutics is also developing TGR-1202 (umbralisib), an orally available PI3K delta inhibitor for various hematologic malignancies.
Weiss said the study was crafted "so those endpoints would be assessed independently and the success of one was not contingent on the success of the other. Had we believed that PFS was contingent on a large difference in ORR, we would have designed the study statistically to reflect that, but we did not. We believe this point has been misunderstood by the street."
TG Therapeutics said the success of the drug's test should be focused on patient survival because "PFS is the gold standard for the FDA."
"Certainly, patients care about living longer without progressive disease. Our drug, umbralisib, is from a class of drugs that are known to provide enhanced PFS and also are known to keep the disease in check versus killing it quickly. So certainly, under the circumstances, PFS is the endpoint that can really showcase the benefit our drug has for patients," said Weiss.
TG Therapeutics is a biopharmaceutical company focused on the acquisition, development and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. The company is based In New York City.
http://www.proactiveinvestors.com/companies/news/205781/tg-therapeutics-ceo-market-reaction-to-unity-cll-drug-was-misplaced-survival-will-be-better-gauge-in-test-205781.html
Recent TGTX News
- New BRIUMVI® (ublituximab-xiiy) Data from the ENHANCE Phase 3b Study Show Rapid 30-Minute Infusions are Well Tolerated in Patients with Relapsing Forms of Multiple Sclerosis • GlobeNewswire Inc. • 09/18/2024 11:15:00 AM
- New Data for BRIUMVI® (ublituximab-xiiy) Demonstrate that 92% of Patients with Relapsing Multiple Sclerosis Were Free from Disability Progression After 5 Years of Treatment • GlobeNewswire Inc. • 09/18/2024 11:00:00 AM
- Palantir Technologies, Dell Technologies, and Erie Indemnity Set to Join S&P 500; Others to Join S&P MidCap 400 and S&P SmallCap 600 • PR Newswire (US) • 09/06/2024 10:43:00 PM
- TG Therapeutics Announces Schedule of Data Presentations for BRIUMVI at the 2024 European Committee for Treatment and Research in Multiple Sclerosis Annual Meeting • GlobeNewswire Inc. • 09/05/2024 11:30:00 AM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/09/2024 08:03:55 PM
- Form 10-K/A - Annual report [Section 13 and 15(d), not S-K Item 405]: [Amend] • Edgar (US Regulatory) • 08/09/2024 08:01:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/06/2024 11:08:39 AM
- TG Therapeutics Reports Second Quarter 2024 Financial Results and Raises BRIUMVI® (ublituximab-xiiy) Full Year Revenue Guidance • GlobeNewswire Inc. • 08/06/2024 11:00:00 AM
- TG Therapeutics to Host Conference Call on Second Quarter 2024 Financial Results and Business Update • GlobeNewswire Inc. • 08/05/2024 11:30:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/17/2024 08:48:08 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 06/17/2024 07:08:53 PM
- Form PX14A6G - Notice of exempt solicitation submitted by non-management • Edgar (US Regulatory) • 06/10/2024 03:23:35 PM
- TG Therapeutics to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference • GlobeNewswire Inc. • 06/07/2024 11:50:00 AM
- TG Therapeutics to Participate in the Jefferies Global Healthcare Conference • GlobeNewswire Inc. • 06/03/2024 11:30:00 AM
- TG Therapeutics Announces Presentations for BRIUMVI® (ublituximab) in Multiple Sclerosis at the 2024 Consortium of Multiple Sclerosis Centers Annual Meeting • GlobeNewswire Inc. • 05/31/2024 11:30:00 AM
- TG Therapeutics Announces Schedule of Upcoming Presentations for BRIUMVI® (ublituximab) in Multiple Sclerosis at the 2024 Consortium of Multiple Sclerosis Centers Annual Meeting • GlobeNewswire Inc. • 05/28/2024 11:30:00 AM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/06/2024 08:59:11 PM
- TG Therapeutics Provides Business Update and Reports First Quarter 2024 Financial Results • GlobeNewswire Inc. • 05/01/2024 11:00:00 AM
- TG Therapeutics to Host Conference Call on First Quarter 2024 Financial Results and Business Update • GlobeNewswire Inc. • 04/30/2024 08:55:29 PM
- TG Therapeutics Announces Additional Data Presentations for BRIUMVI® (ublituximab-xiiy) in Multiple Sclerosis at the American Academy of Neurology 2024 Annual Meeting • GlobeNewswire Inc. • 04/18/2024 11:30:00 AM
- TG Therapeutics Awarded National Contract by the Department of Veterans Affairs for BRIUMVI as the Preferred Anti-CD20 for Relapsing Forms of Multiple Sclerosis • GlobeNewswire Inc. • 04/18/2024 11:00:00 AM
- TG Therapeutics Announces Presentation of Data for BRIUMVI® (ublituximab-xiiy) in Multiple Sclerosis at the American Academy of Neurology 2024 Annual Meeting • GlobeNewswire Inc. • 04/15/2024 11:30:00 AM
- TG Therapeutics Announces Schedule of Data Presentations for BRIUMVI® (ublituximab) in Multiple Sclerosis at the American Academy of Neurology 2024 Annual Meeting • GlobeNewswire Inc. • 03/08/2024 12:30:00 PM
- TG Therapeutics Announces Presentation of Data for BRIUMVI® in Multiple Sclerosis at the Americas Committee for Treatment and Research in Multiple Sclerosis Annual Forum • GlobeNewswire Inc. • 03/01/2024 12:30:00 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 02/29/2024 10:23:27 PM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM
Element79 Gold Corp. Appoints Kevin Arias as Advisor to the Board of Directors, Strengthening Strategic Leadership • ELMGF • Sep 18, 2024 10:29 AM
Mawson Finland Limited Further Expands the Known Mineralized Zones at Rajapalot: Palokas step-out drills 7 metres @ 9.1 g/t gold & 706 ppm cobalt • MFL • Sep 17, 2024 9:02 AM
PickleJar Announces Integration With OptCulture to Deliver Holistic Fan Experiences at Venue Point of Sale • PKLE • Sep 17, 2024 8:00 AM